Dr David Hughes has been promoted to the role of Chief Technology Officer, effective immediately. In his new role, he will take responsibility for overseeing management of all technical projects and alliances with CN Bio partners. He will also continue to manage the internal scientific and engineering teams.
Dr Hughes joined the Company in 2010 as Head of Engineering and was promoted to Technical Director in February 2013. He has been pivotal in securing contracts with leading pharmaceutical companies and has been lead principal investigator on several UK, EU and US grants including currently the EU FP7 BIO-MIMETICS project. As co-principal investigator on a $26 Mi US DARPA contract, Dr Hughes has contributed to the strategic direction of this program as well as leading the company’s participation and delivery of milestones under the contract. Prior to joining CN Bio, Dr Hughes graduated from the University of Oxford with a Masters in Engineering Science and Doctorate in Chemical Engineering. After that he spent three years in industry at GSK.
Dr David Scales, CEO of CN Bio said: “The Board are delighted to make this appointment in recognition of the outstanding contribution David has made to the company’s technical progress over the past year or so. He will now take a senior leadership role at an important new phase for the company as we enter a number of key academic and industrial collaborations. I welcome David’s continued commitment and energy for the business.”